Tag Archives: decline

Head traumas may lead to Alzheimer’s

Brain injuries sustained on the battlefield and the gridiron of American football likely boost the risk of dementia later in life, according to two studies released Monday.

In a third study, also presented at an international Alzheimer’s conference in Paris this week, researchers unveiled evidence that falling over in daily life may be an early warning sign of the onset of Alzheimer’s.

Older war veterans who experienced traumatic brain injury face a doubled risk of developing dementia, according to a study led by Kristine Yaffe, head of the Memory Disorders Program at the San Francisco Veterans Association medical centre.

Reviewing the medical records of 281,540 US veterans aged 55 and older, they found that the risk of dementia was 15.3 percent in those who had had traumatic brain injuries (TBI) compared to 6.8 percent for ex-soldiers who had not.

“This issue is important, because TBI is very common,” Yaffe said in a statement.

“About 1.7 million people experience a TBI each year in the United States, primarily due to falls and car crashes.”

Such injuries are also known as the “signature wound” of the conflicts in Afghanistan and Iraq, accounting for 22 percent of casualties overall and 59 percent of blast-related injuries.

The research suggests that the death and damage of axons – long cell extensions that form connections among nerve cells in the brain – may be to blame for the higher risk of dementia.

Alzheimer's disease

Alzheimer's disease

The swelling of the traumatised axons accompanies the accumulation of proteins called beta-amyloid, a hallmark of Alzheimer’s.

Amyloid plaques similar to those found in the brains of people with Alzheimer’s are present in up to 30 percent of TBI patients who do not survive their injuries, regardless of age.

In the second study, scientists led by Christopher Randolph of Loyola University Medical Center in Chicago compared the likelihood of decline in basic cognitive functions among retired football players and in older adults who had not played professional sports.

The repeated head-on clashes typical of American football may – despite protective gear – boost the chances of long-term brain damage.

Of more than 500 ex-football players, mean age 61, who responded to a health survey in 2008, just over 35 percent gave answers suggesting possible dementia, nearly triple the rate of Alzheimer’s among Americans over 65.

Researchers followed up on this data to identify players with Mild Cognitive Disorder (MCI), often a precursor to full-blown dementia or Alzheimer’s.

The study compared neurological and psychological test results from this group with two other groups, neither of which had played pro sports: demographically similar adults who showed no cognitive decline, and adults diagnosed with MCI.


The former athletes were clearly impaired compared to the normal adults. They were slightly less impaired that the non-athlete group diagnosed with MCI, but were considerably younger.

“It appears that there may be a very high rate of cognitive impairment in these retired football players compared to the general population,” Randolph said, pointing to “repetitive head trauma” as the likely culprit.

In the last study, Washington University researcher Susan Stark and colleagues tracked 125 older adults over eight months, asking them to log any falls they made in day-to-day life.

Those adults with so-called preclinical Alzheimer’s – signs measurable in brain scans even in the absence of memory loss – were nearly three times more likely to fall for each notch on a scale used to measure Alzheimer’s progression.

“This study suggests that higher rates of falls can occur very early in the disease process,” said Stark.

Traditional hallmarks of Alzheimer’s such as memory loss remain critically important, said Maria Carrillo, a senior director at the Alzheimer’s Association in the United States, commenting on the study.

“But these results also illustrate the significance of understanding that, in some people, changes in gait and balance may appear before cognitive impairment,” she said.

Memantine and Alzheimer’s

A drug frequently prescribed to treat people with mild Alzheimer’s disease does not appear to be an effective therapy for many of these patients, according to a new study.

The results show the drug, memantine, is no better than a dummy pill when it comes to ameliorating disease symptoms, including the decline of mental abilities, the researchers say. There is also meager evidence that the drug works for patients with moderate Alzheimer’s, the researchers say.

Memantine is approved by the Food and Drug Administration to treat patients with moderate and severe Alzheimer’s. However, physicians often prescribe it off-label to those with mild forms of the disease. About 19 percent of U.S. patients with mild Alzheimer’s disease take the drug, the researchers say. The drug is intended to improve cognitive functions and make it easier for patients to perform daily activities.

Though there is no proof that the drug thwarts disease progress, some physicians may prescribe it, and some patients may take it, “under the hopes that it’s better to treat with this drug now rather than it is to wait until somebody becomes severe and then treat them,” said study researcher Dr. Lon Schneider, of the University of Southern California Keck School of Medicine in Los Angeles.

Alzheimer's

Alzheimer's

Doctors should take into account these new findings when they consider treating mild and moderate Alzheimer’s patients with memantine, Schneider said. Additional studies should be conducted looking at the effects of memantine on patients with mild disease, Schneider said.

Experts agree it’s too early to say whether physicians should stop prescribing this drug for patients with mild Alzheimer’s disease. “Physicians should become as educated as possible about the drugs and use them with their best judgment,” said William Thies, chief medical and scientific officer at the Alzheimer’s Association, who was not involved in the study. “The success or lack of success is such a close call, and the effects are so small, I think a blanket recommendation is very hard to give at this point,” Thies said.

The study was published online Monday in the journal Archives of Neurology.

It is estimated that as many as 5 million Americans have Alzheimer’s disease, according to the Centers for Disease Control and Prevention. Patients are categorized as having mild, moderate or severe forms of the disease depending on how well they score on a test designed to assess mental abilities. Patients with lower scores have a higher degree of mental impairment. Studies investigating the effects of memantine on Alzheimer’s disease have generally grouped mild and moderate patients together, and so the effects on just those with mild form of the disease were unclear.


Schneider and his colleagues analyzed three studies that had randomly assigned patients to receive either memantine or a placebo. These studies included 431 patients with mild Alzheimer’s and 697 patients with moderate Alzheimer’s. The researchers were able to extract the information on patients with mild Alzheimer’s disease and examine it separately.

Mild Alzheimer’s patients on the drug fared no better than patients on the placebo in terms of improvement of symptoms and their ability to carry out daily activities.

The drug had a small effect on those with moderate Alzheimer’s disease when the researchers combined information from the three trials.

Thies notes patients can vary widely in their response to the drug. It’s possible that some patients with mild Alzheimer’s disease do improve significantly, but these positive effects are hidden because many other patients in the trial do not improve.

“We don’t have a good way of picking out who will respond ahead of time,” Thies said.

Further studies may provide a better idea of which patients benefit most from the drug, but this information would be hard to tease out, Thies said.